Are you interested in learning about new, emerging therapies that could potentially restore hearing? Would you like to stay apprised of new clinical trials for individuals with sensorineural hearing loss (SNHL) – and learn how to enroll?
In this program, Frequency Therapeutics’ Chief Development Officer, Dr. Carl LeBel, will provide an overview of outcomes from four completed clinical trials of FX-322, the Company’s product candidate, which is the first to have shown meaningful hearing improvements in clinical studies. Individuals that showed these improvements included those with a range of hearing loss severities and causes, and Dr. LeBel will discuss the types of hearing loss where Frequency is currently focused. Grace Fitzgerald, Director of Clinical Operations for Frequency, will share information about a current clinical trial for FX-322 with sites across the country and opportunities for individuals to enroll. A Q&A discussion will follow the presentation.
Frequency’s hearing program focuses on addressing the underlying cause of SNHL by regenerating cells in the ear that are necessary for healthy hearing.